Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.39 |
| ▸ | CAT | P04040 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8948537 | 0.86 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAPKMNPSR1 | |
| SCHEMBL8939953 | 0.81 | PKM (0.44) | ALDH1A1MAPTLMNAPKMNPSR1 | |
| SCHEMBL30888662 | 0.80 | FFAR4 (0.41) | ALDH1A1MAPTLMNAPKMNPSR1 | |
| SCHEMBL2433641 | 0.80 | FFAR4 (0.41) | ALDH1A1MAPTLMNAPKMNPSR1 | |
| SCHEMBL8948775 | 0.73 | ALDH1A1 (0.39) | ALDH1A1MAPTLMNAPKMNPSR1 | |
| SCHEMBL9221067 | 0.71 | ALDH1A1 (0.39) | ALDH1A1CATNPC1RAB9A | |
| SCHEMBL783714 | 0.71 | LMNA (0.59) | ALDH1A1MAPTLMNAPKMNPSR1 | |
| SCHEMBL8390687 | 0.71 | PKM (0.43) | ALDH1A1MAPTLMNAPKMNPSR1 | |
| SCHEMBL31474106 | 0.71 | ALDH1A1 (0.43) | ALDH1A1MAPTLMNAPKMNPSR1 | |
| SCHEMBL8388445 | 0.71 | KMT2A (0.43) | ALDH1A1MAPTLMNAPKMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5563148-A | BICYCLIC ESTERS OR AMIDES; USED IN TREATING MIGRAINE, EMESIS, GASTROINTESTINAL DISORDERS, SCHIZOPHRENIA OR ANXIETY IN MAMMALS | ELI LILLY AND COMPANY (US) | 1996-10-08 | — | — | US | disclosed |
| EP-0307172-B1 | Improvements in or relating to specific 5-HT3 antagonists | LILLY CO ELI (US) | 1995-10-11 | — | — | EP | disclosed |
| US-5442078-A | Intermediates for specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5364863-A | Treatment of migraine, emesis, schizophrenia, anxiety, gastrointestinal disorders | ELI LILLY AND COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| US-4997956-A | Analgesics | ELI LILLY AND COMPANY (US) | 1991-03-05 | — | — | US | disclosed |
| US-4921982-A | 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| CN-1031841-A | The improvement of special 5-HT3 antagonist | LILLY CO ELI (US) | 1989-03-22 | — | — | CN | disclosed |
| EP-0307172-A2 | Improvements in or relating to specific 5-HT3 antagonists | ELI LILLY AND COMPANY (US) | 1989-03-15 | — | — | EP | disclosed |